Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Targeting p53 for Novel Anticancer Therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
The hallmarks of cancer
10.1016/s0092-8674(00)81683-9 · 2000 · External reference
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
10.1016/0092-8674(79)90293-9 · 1979 · External reference
Tantigen is bound to a host protein in SV40-transformed cells
10.1038/278261a0 · 1979 · External reference
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
10.1126/science.2649981 · 1989 · External reference
The p53 proto-oncogene can act as a suppressor of transformation
10.1016/0092-8674(89)90045-7 · 1989 · External reference
Molecule of the year
10.1126/science.8266084 · 1993 · External reference
The genetics of the p53 pathway, apoptosis and cancer therapy
10.1038/nrd2656 · 2008 · External reference
Surfing the p53 network
10.1038/35042675 · 2000 · External reference
Mdm2 promotes the rapid degradation of p53
10.1038/387296a0 · 1997 · External reference
Regulation of p53 stability by Mdm2
10.1038/387299a0 · 1997 · External reference
The ubiquitin ligase COP1 is a critical negative regulator of p53
10.1038/nature02514 · 2004 · External reference
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation
10.1016/s0092-8674(03)00193-4 · 2003 · External reference
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
10.1038/sj.onc.1203434 · 2000 · External reference
The complexity of p53 modulation: emerging patterns from divergent signals
10.1101/gad.12.19.2973 · 1998 · External reference
p53: puzzle and paradigm
10.1101/gad.10.9.1054 · 1996 · External reference
Post-translational modification of p53 in tumorigenesis
10.1038/nrc1455 · 2004 · External reference
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
10.1016/s0955-0674(03)00003-6 · 2003 · External reference
Protein methylation: a new mechanism of p53 tumor suppressor regulation
2008 · External reference
p53, the cellular gatekeeper for growth and division
10.1016/s0092-8674(00)81871-1 · 1997 · External reference
Cytoplasmic functions of the tumour suppressor p53
10.1038/nature07986 · 2009 · External reference
Decision making by p53: life, death and cancer
10.1038/sj.cdd.4401183 · 2003 · External reference
Transcriptional repression mediated by the p53 tumour suppressor
10.1038/sj.cdd.4401191 · 2003 · External reference
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer
10.1242/jcs.013029 · 2008 · External reference
p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter
10.1515/bc.2008.039 · 2008 · External reference
Transcriptional control of human p53-regulated genes
10.1038/nrm2395 · 2008 · External reference
p53 and its downstream proteins as molecular targets of cancer
10.1002/mc.20231 · 2006 · External reference
Cellular senescence: when bad things happen to good cells
10.1038/nrm2233 · 2007 · External reference
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy
10.1016/s0092-8674(02)00734-1 · 2002 · External reference
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
10.1007/s00109-007-0221-2 · 2007 · External reference
Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin
10.1126/stke.3542006pe35 · 2006 · External reference
p53: the Janus of autophagy?
2008 · External reference
The dark side of a tumor suppressor: anti-apoptotic p53
10.1038/cdd.2008.33 · 2008 · External reference
Database of p53 gene somatic mutations in human tumors and cell lines
1994 · External reference
Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture
1999 · External reference
Functions of the MDM2 oncoprotein
10.1007/s000180050273 · 1999 · External reference
The role of p53 in chemosensitivity and radiosensitivity
10.1038/sj.onc.1206949 · 2003 · External reference
p53 status and the efficacy of cancer therapy in vivo
10.1126/science.7973635 · 1994 · External reference
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
10.1016/0092-8674(93)90719-7 · 1993 · External reference
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma
1996 · External reference
Role of p53 in drug resistance in ovarian cancer
10.1016/s0140-6736(05)60195-x · 1997 · External reference
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains
10.1002/gcc.2870140113 · 1995 · External reference
The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies
10.1046/j.1365-2141.1997.2403057.x · 1997 · External reference
The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers
10.1007/bf01220804 · 1996 · External reference
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
1997 · External reference
Targeting p53 for enhanced radio- and chemosensitivity
10.1007/s10495-009-0330-1 · 2009 · External reference
A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status
10.1080/09553000801953342 · 2008 · External reference
The role of p53 in determining sensitivity to radiotherapy
10.1038/nrc992 · 2003 · External reference
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
10.1016/s0140-6736(02)09969-5 · 2002 · External reference
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
1995 · External reference
Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells
1997 · External reference
p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines
10.1046/j.1365-2184.1996.01009.x · 1996 · External reference
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
10.1172/jci6863 · 1999 · External reference
A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis
1993 · External reference
Adenovirus p53 gene therapy
10.1517/14712598.6.1.55 · 2006 · External reference
China approves first gene therapy
10.1038/nbt0104-3 · 2004 · External reference
p53 as a target for anti-cancer drug development
10.1016/j.critrevonc.2005.10.005 · 2006 · External reference
Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers
10.1089/hum.2005.16.1016 · 2005 · External reference
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
10.1126/science.274.5286.373 · 1996 · External reference
ONYX-015, an E1B gene-attenuated adenovirus, causes tumorspecific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
10.1038/nm0697-639 · 1997 · External reference
In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
2000 · External reference
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration
2000 · External reference
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
10.1038/78638 · 2000 · External reference
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
10.1038/nm1146 · 2004 · External reference
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
10.1038/nm1105-1135 · 2005 · External reference
Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis
10.1016/j.ccr.2009.03.021 · 2009 · External reference
Dangerous habits of a security guard: the two faces of p53 as a drug target
10.1093/hmg/ddm052 · 2007 · External reference
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
10.1126/science.285.5434.1733 · 1999 · External reference
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation
10.1038/nchembio809 · 2006 · External reference
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations
10.1093/emboj/17.7.1847 · 1998 · External reference
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
10.1038/sj.onc.1210295 · 2007 · External reference
ASPP proteins specifically stimulate the apoptotic function of p53
10.1016/s1097-2765(01)00367-7 · 2001 · External reference
A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants
10.1073/pnas.241629998 · 2002 · External reference
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
10.1073/pnas.1835733100 · 2003 · External reference
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived fromthe p53 C-terminal domain
10.1038/nm0697-632 · 1997 · External reference
Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells
10.1074/jbc.274.49.34924 · 1999 · External reference
Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide
10.1371/journal.pbio.0020036 · 2004 · External reference
Pharmacological rescue of mutant p53 conformation and function
10.1126/science.286.5449.2507 · 1999 · External reference
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
10.1038/sj.onc.1205362 · 2002 · External reference
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding
10.1128/mcb.23.6.2171-2181.2003 · 2003 · External reference
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein
10.4161/cbt.1.1.41 · 2002 · External reference
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice
10.1172/jci32481 · 2007 · External reference
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
10.1038/nm0302-282 · 2002 · External reference
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
10.1074/jbc.m501664200 · 2005 · External reference
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
10.1016/j.ccr.2009.03.003 · 2009 · External reference
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway
10.1158/1535-7163.mct-04-0206 · 2005 · External reference
Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells
10.1186/bcr1290 · 2005 · External reference
PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells
10.1002/jcb.21794 · 2008 · External reference
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status
10.1016/j.radonc.2008.01.001 · 2008 · External reference
PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis
10.1038/sj.onc.1208419 · 2005 · External reference
Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity
10.1124/mol.53.2.241 · 1998 · External reference
Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine
1999 · External reference
Rescue of mutant p53 transcription function by ellipticine
10.1038/sj.onc.1206777 · 2003 · External reference
A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization
10.1007/s10495-007-0175-4 · 2008 · External reference
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway
10.4161/cbt.6.3.3703 · 2007 · External reference
Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action
10.1093/carcin/16.4.767 · 1995 · External reference
The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway
10.1038/sj.onc.1203413 · 2000 · External reference
Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiolWR1065 in the esophageal cancer cell line TE-1
10.1002/mc.10038 · 2002 · External reference
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
10.1038/sj.cdd.4402301 · 2008 · External reference
The concept of synthetic lethality in the context of anticancer therapy
10.1038/nrc1691 · 2005 · External reference
Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets
10.2174/156652408786733676 · 2008 · External reference
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
10.1073/pnas.171076798 · 2001 · External reference
Use of isogenic human cancer cells for high-throughput screening and drug discovery
10.1038/nbt1001-940 · 2001 · External reference
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells
10.1158/0008-5472.can-05-4602 · 2006 · External reference
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
10.1016/s1535-6108(04)00113-8 · 2004 · External reference
Identification of a small molecule with synthetic lethality for K-ras and protein kinase Cι
10.1158/0008-5472.can-08-1449 · 2008 · External reference
An informationintensive approach to the molecular pharmacology of cancer
10.1126/science.275.5298.343 · 1997 · External reference
DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4
1999 · External reference
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
10.1158/0008-5472.can-06-4447 · 2007 · External reference
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
10.1093/jnci/88.14.956 · 1996 · External reference
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator
2001 · External reference
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
10.1073/pnas.0813333106 · 2009 · External reference
Activation of an MDM2-specific caspase by p53 in the absence of apoptosis
10.1074/jbc.274.21.15271 · 1999 · External reference
Global Genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinomas
10.4161/cbt.2.4.437 · 2003 · External reference
Cardiac glycosides inhibit p53 protein synthesis by a mechanism relieved by Src or MAPK inhibitors
10.1158/0008-5472.can-09-0891 · 2009 · External reference
Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth
10.1152/ajpcell.00098.2007 · 2007 · External reference
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation
10.1016/j.ccr.2006.08.013 · 2006 · External reference
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
10.1038/ncb1571 · 2007 · External reference
The p53-mdm-2 autoregulatory feedback loop
10.1101/gad.7.7a.1126 · 1993 · External reference
Molecular analysis and chromosomal mapping of amplified genes isolated froma transformed mouse 3T3 cell line
10.1007/bf01535205 · 1987 · External reference
Control of p53 ubiquitination and nuclear export by MDM2 and ARF
2001 · External reference
The MDM2 gene amplification database
10.1093/nar/26.15.3453 · 1998 · External reference
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
10.1038/378203a0 · 1995 · External reference
The loss of mdm2 induces p53-mediated apoptosis
10.1038/sj.onc.1203468 · 2000 · External reference
p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
10.1038/sj.onc.1202528 · 1999 · External reference
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms
10.1007/bf03402011 · 2002 · External reference
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
10.1126/science.274.5289.948 · 1996 · External reference
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
10.1073/pnas.0708917105 · 2008 · External reference
Structural and functional basis for therapeutic modulation of p53 signaling
10.1158/1078-0432.ccr-08-1526 · 2008 · External reference
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
10.1126/science.1092472 · 2004 · External reference
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
10.1021/jm049137g · 2005 · External reference
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction
10.1021/jm051122a · 2006 · External reference
A small molecule that disruptsMdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy
10.4161/cbt.7.6.5841 · 2008 · External reference
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
10.1158/1535-7163.mct-05-0199 · 2006 · External reference
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
10.1038/leu.2008.11 · 2008 · External reference
Inactivation of the p53 pathway in retinoblastoma
10.1038/nature05194 · 2006 · External reference
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
10.1158/1535-7163.mct-07-0442 · 2008 · External reference
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
10.1158/1535-7163.mct-05-0356 · 2006 · External reference
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
10.1182/blood-2005-08-3273 · 2006 · External reference
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
10.1182/blood-2005-12-5148 · 2006 · External reference
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
10.1158/1535-7163.mct-06-0305 · 2006 · External reference
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
10.1074/jbc.m606928200 · 2007 · External reference
Nongenotoxic p53 activation protects cells against S-phase.specific chemotherapy
10.1158/0008-5472.can-06-1527 · 2006 · External reference
The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies
10.2174/138161208785294663 · 2008 · External reference
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
10.1158/1535-7163.mct-08-0140 · 2008 · External reference
Targeting the MDM2-p53 interaction for cancer therapy
10.1158/1078-0432.ccr-07-5136 · 2008 · External reference
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
10.1016/j.ccr.2005.04.029 · 2005 · External reference
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
10.1038/sj.onc.1210707 · 2008 · External reference
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1
10.1038/sj.onc.1210136 · 2007 · External reference
Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1α and Hdm2
10.1158/0008-5472.can-06-2710 · 2007 · External reference
Regulation of XIAP translation and induction by MDM2 following irradiation
10.1016/j.ccr.2009.03.002 · 2009 · External reference
Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction
10.1101/gad.1467506 · 2006 · External reference
Sirtuins in mammals: insights into their biological function
10.1042/bj20070140 · 2007 · External reference
Structural identification of 2′ and 3′-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of β-NAD+-dependent histone/protein deacetylases
10.1074/jbc.m200671200 · 2002 · External reference
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo
10.1073/pnas.0308762101 · 2004 · External reference
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence
10.1093/emboj/21.10.2383 · 2002 · External reference
Negative control of p53 by Sir2α promotes cell survival under stress
10.1016/s0092-8674(01)00524-4 · 2001 · External reference
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase
10.1016/s0092-8674(01)00527-x · 2001 · External reference
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator
10.1016/j.ccr.2008.03.004 · 2008 · External reference
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen
10.4161/cc.7.21.6982 · 2008 · External reference
p73 is a simian [correction of human] p53-related protein that can induce apoptosis
10.1038/38298 · 1997 · External reference
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
10.1016/s1097-2765(00)80275-0 · 1998 · External reference
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family
10.1016/j.ccr.2005.02.019 · 2005 · External reference
p63 and p73 in human cancer: defining the network
10.1038/sj.onc.1210337 · 2007 · External reference
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
10.1038/sj.onc.1210311 · 2007 · External reference
Targeting the p53 family for cancer therapy: “big brother‘ joins the fight
10.4161/cc.6.16.4614 · 2007 · External reference
Therapeutic prospects for p73 and p63: rising from the shadow of p53
10.1016/j.drup.2008.08.001 · 2008 · External reference
Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application to gene therapy of colorectal cancer
10.1038/sj.gt.3301538 · 2001 · External reference
Antitumor effect of adenovirusmediated p53 family gene transfer on osteosarcoma cell lines
10.4161/cbt.6.7.4320 · 2007 · External reference
p73 β-expressing recombinant adenovirus: a potential anticancer agent
10.1038/sj.cgt.7700803 · 2005 · External reference
Physical and functional interaction between p53 mutants and different isoforms of p73
10.1074/jbc.m003360200 · 2000 · External reference
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities
10.1074/jbc.m201405200 · 2002 · External reference
The disruption of the protein complex mutant p53/p73 increases selectively the response of tumor cells to anticancer drugs
10.4161/cc.7.21.6995 · 2008 · External reference
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo
10.1172/jci28920 · 2007 · External reference
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts
10.1073/pnas.0604507103 · 2006 · External reference
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
10.1073/pnas.0802091105 · 2008 · External reference
A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells
10.1038/sj.onc.1208888 · 2005 · External reference
A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death
10.1126/science.1098231 · 2004 · External reference
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP
10.1158/0008-5472.can-08-2655 · 2008 · External reference
Strategies for manipulating the p53 pathway in the treatment of human cancer
2000 · External reference
Cancer prevention research—then and now
10.1038/nrc2646 · 2009 · External reference
Can green tea do that? A literature review of the clinical evidence
10.1016/j.ypmed.2009.05.005 · 2009 · External reference
Cancer chemoprevention through dietary antioxidants: progress and promise
10.1089/ars.2007.1740 · 2008 · External reference
Cancer chemoprevention by garlic and its organosulfur compounds—panacea or promise?
10.2174/187152008783961879 · 2008 · External reference
